S
Sven Stanzel
Researcher at Hoffmann-La Roche
Publications - 7
Citations - 396
Sven Stanzel is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Trastuzumab emtansine & Cancer. The author has an hindex of 3, co-authored 7 publications receiving 280 citations.
Papers
More filters
Journal ArticleDOI
Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
Edith A. Perez,Carlos H. Barrios,Wolfgang Eiermann,Masakazu Toi,Young-Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Jennifer A. Petersen,Sven Stanzel,Alexander Strasak,Monika Patre,Paul Ellis +14 more
TL;DR: T-DM1 showed noninferior, but not superior, efficacy and better tolerability than did taxane plus trastuzumab for first-line treatment of HER2-positive, advanced breast cancer.
Journal ArticleDOI
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Edith A. Perez,Sanne de Haas,Wolfgang Eiermann,Carlos H. Barrios,Masakazu Toi,Young Hyuck Im,Pierfranco Conte,Miguel Martin,Tadeusz Pienkowski,Xavier Pivot,Howard A. Burris,Sven Stanzel,Monika Patre,Paul Anthony Ellis +13 more
TL;DR: In MARIANNE, biomarkers related to the HER2 pathway did not have predictive value for PFS when comparing T-DM1 (with or without pertuzumab) with trastuzuab plus taxane, however, HER2 mRNA level and PIK3CA mutation status showed prognostic value.
Journal ArticleDOI
Efficacy, safety, and biomarker results of trastuzumab emtansine (T-DM1) in patients (pts) with previously treated HER2-overexpressing locally advanced or metastatic non-small cell lung cancer (mNSCLC).
T. Stinchcombe,Rolf A. Stahel,Lukas Bubendorf,Philip Bonomi,Augusto E. Villegas,Dariusz M. Kowalski,Christina S. Baik,Dolores Isla,Javier de Castro,Pilar Garrido Lopez,Achim Rittmeyer,Marcello Tiseo,Sven Stanzel,Sanne de Haas,Lisa H. Lam,Michael T. Lu,Solange Peters +16 more
TL;DR: T-DM1 is an antibody-drug conjugate approved for HER2-positive metastatic breast cancer and primary results from a fully enrolled, ongoing phase 2 study (NCT02289833) of pts are reported.
Journal ArticleDOI
1008P IMbrave150: Management of adverse events of special interest (AESIs) for atezolizumab (atezo) and bevacizumab (bev) in unresectable HCC
Masafumi Ikeda,Andrew X. Zhu,S. Qin,T-Y. Kim,H.Y. Lim,Masatoshi Kudo,V. Breder,Philippe Merle,Ahmed Kaseb,Daneng Li,Ning Ma,M. Villalobos,Sven Stanzel,Vincent E. Gaillard,D-Z. Xu,Sairy Hernandez,A-L Cheng,Richard S. Finn,Peter R. Galle,Michel Ducreux +19 more
Proceedings ArticleDOI
Abstract CT185: Assessment of the impact of anti-drug antibodies on PK and clinical outcomes with atezolizumab + bevacizumab in HCC
Peter R. Galle,Richard S. Finn,Ann-Lii Cheng,Coen Bernaards,Colby S. Shemesh,Alexandr Vilimovskij,Wendy Verret,Sven Stanzel,Ning Ma,Michel Ducreux,Andrew X. Zhu +10 more
TL;DR: While there were some numerical differences in AE rates between ADA+ and ADA− pts, ADAs did not have a clinically significant effect on the incidence or severity of AEs, and PFS and ORR benefits vs sor were clinically meaningful and similar between ADA subgroups.